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Acute pharmacotherapy of migraine,
tension-type headache, and cluster headache
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Abstract In most migraine patients
acute therapy is needed. Migraine
can be treated either with specific
drugs, the triptans and ergot alka-
loids, or with NSAIDs. Triptans
are a major step foreward in
migraine therapy. The therapeutic
gain for headache relief is 50% for
subcutaneous sumatriptan whereas
it is 30-40% for most oral triptans.
After oral triptans sustained pain
free is only 30%. There is thus still
ample room for improvement of
acute therapy in migraine. For ten-
sion-type headache there is no spe-
cific therapy and it is treated with
NSAIDs. Only 17-32% become
pain free after these drugs. For
attacks of cluster headache oxygen
and subcutaneous sumatriptan can
be used. Intranasal triptans can be
an alternative.
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The quality of acute pharmacotherapy of migraine has
improved recently with the advent of the new specific drugs,
the triptans. For tension-type headache there has not been a
similar development of specific drugs and tension-type
headache is still treated with mild analgesics and non-
steroidal anti-inflammatory drugs (NSAIDs). Cluster
headache is also responding to triptan therapy.
Acute pharmacotherapy of migraine
Migraine can be regarded as an episodic-chronic disorder
[1] and in the treatment of migraine one should consider
treatment of the migraine attacks and in many cases also
preventive treatment. Even with successful prophylactic
treatment of migraine the patients will in most cases still
suffer from some migraine attacks and need treatment for
these. So optimum treatment of acute migraine attacks is
the first priority in most cases.
Acute migraine attacks can be treated with either
unspecific drugs such as aspirin and NSAIDs or specific
medicines like triptans and ergot alkaloids. In addition,
prokinetic drugs and neuroleptics may be useful.
Unspecific treatment of migraine attacks
A new highly buffered formulation of 1000 mg efferves-
cent aspirin (53% relief) was similar in efficacy to suma-
triptan 50 mg (56% relief) and ibuprofen 400 mg (60%
relief) in a large placebo-controlled (31% relief) study [2].
Other NSAIDs with proven efficacy in acute migraine
treatment are naproxen, ketoprofen, tolfenamic acid and
diclofenac potassium [3]. The NSAID indomethacin plus
prochlorperazine plus caffeine suppositories (49% pain
free) was more effective than sumatriptan suppositories
(34% pain free) in one randomised clinical trial (RCT)
[4]. Frequent intake of analgesics, 15 days or more per
month, leads to chronic headache and medication overuse
headaches, and this can also happen with over-the-counter
drugs [5].
Specific treatment of migraine attacks
Triptans
The 5-HT1B/1D receptor agonists, the triptans, have been
compared in several meta-analyses of placebo-controlled
RCTs [6–10] and in head-to-head comparative RCTs [10].
An example of such a meta-analysis is shown in Table 1.
Subcutaneous sumatriptan has the highest therapeutic
gain (TG) (percentage response after active drug minus
percentage response after placebo) of 51% (95 confidence
intervals (CI); 48–53%). Eletriptan 80 mg (mean
TG=42%, 95%CI: 37–47%) was also superior to suma-
triptan 100 mg (mean TG=32%, 95%CI: 29–34%).
Frovatriptan 2.5 mg (mean TG=16%, 95% CI: 8–25%)
and naratriptan 2.5 mg (mean TG=22%, 95% CI: 18–26%)
were both inferior to the standard triptan, sumatriptan 100
mg. All the other triptans and other administration forms
of sumatriptan were roughly comparable to sumatriptan
100 mg (see Table 1).
In head-to-head comparative RCTs zolmitriptan 5 mg
[11], rizatriptan 10 mg [12] and almotriptan 12.5 mg [11]
were comparable to sumatriptan 100 mg for headache
relief (a decrease from moderate or severe to none or
mild). In a review of 3 comparative RCTs eletriptan 40 mg
(67%) was superior to sumatriptan 100 mg (57%) [13].
Rizatriptan 10 mg (40%) was superior to sumatriptan 100
mg (33%) for pain-free after 2 h [12]. Similarly, eletriptan
40 mg (35%) was superior to sumatriptan 100 mg (25%)
for pain-free after 2 h in 3 RCTs [13].
Based on the quicker absorption of rizatriptan than
sumatriptan, the two triptans have to be compared for time
to headache relief in 3 RCTs [11]. In two of these RCTs
rizatriptan 10 mg had a quicker onset of action than suma-
triptan 50 mg and 100 mg [12, 14], whereas this was not
the case in the third RCT [15]. It should be noted that this
time-to-event analysis cannot distinguish onset of action
from one drug being marginally superior to the other. Thus
this analysis apparently showed that rizatriptan 10 mg had
a quicker onset of action than rizatriptan 5 mg [16].
Head-to-head comparisons of triptans with other drugs
are shown in Table 2. The 3 oral triptans, sumatriptan,
rizatriptan and eletriptan, were superior to oral ergota-
mine. In contrast, rectal ergotamine 2 mg (73% relief) was
superior to rectal sumatriptan 25 mg [11]. Sumatriptan
100 mg (75%) was superior to tolfenamic acid (58%) for
headache relief [17]. Highly buffered aspirin, aspirin plus
metoclopramide, and lysine acetylsalicylic acid plus
metoclopramide were comparable to sumatriptan 50 mg
and 100 mg [11]. Diclofenac potassium was comparable
Table 1 Mean TGa for different triptans and forms of administration based on published papers and abstracts (for references and number
of patients, see  [9, 11])
Drug Dose (mg) Mean TGb (%) 95% CIs (%)
Sumatriptan Subc. 6 51 48–53
Sumatriptan Oral 100 32 29–34
Sumatriptan Oral 50 29 25–34
Sumatriptan Oral 25 24 18–29
Sumatriptan Nasal 20 30 25–34
Sumatriptan Rectal 25 31 25–37
Zolmitriptan Oral 2.5 32 26–38
Naratriptan Oral 2.5 22 18–26
Rizatriptan Oral 10 37 34–40
Rizatriptan Oral 5 28 23–34
Rizatriptan Waferc 10 37 29–45
Eletriptan Oral 80 42 37–47
Eletriptan Oral 40 37 32–42
Almotriptan Oral 12.5 26 20–32
Frovatriptan Oral 2.5 16 8–25
aPercentages headache relief after active drug minus percentage headache relief after placebo; bbased on headache relief (a decrease from severe
or moderate headache to none or mild after 2 h (for subcutaneous sumatriptan after 1 h)); ca rapidly dissolving wafer
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to sumatriptan in one RCT [11]. Subcutaneous sumatrip-
tan 6 mg was comparable to subcutaneous dihydroergota-
mine 1 mg (DHE) [11, 18]. Intranasal sumatriptan 20 mg
(63% relief) was superior to intranasal 1 mg+1 mg DHE
(51% relief) [19].
Recently, patients have treated their migraine attacks
in the mild phase of migraine in RCTs. Pain-free after 2
h has been the primary efficacy measure in these RCTs.
Rizatriptan 10 mg resulted in 70% being pain-free [20]
and sumatriptan 100 mg resulted in 58% being pain-free
[21] in double-blind, placebo-controlled RCTs. These
results are considerable higher than the 30% pain-free
found for most triptans when moderate or severe attacks
are treated [7, 8]. If patients can distinguish the mild
phase of migraine from a tension-type headache, treat-
ment with a triptan in the mild phase can be recom-
mended.
The clinical use of the triptans is shown in Table 3. The
oral route is used in most cases but if the patient has
severe nausea or is actually vomiting, other routes of
Table 2 RCTs comparing triptans with non-triptan drugs (for further details see  [9–11]). Significant differences are shown in bold italics
Drug Dose (mg) Headache reliefa (%) Difference (%) 95% CIb
Sumatriptan Oral 100 66 +18 +9 to +27%
Ergotamine+caffeine Oral 2+200 48
Sumatriptan Oral 50 57
Aspirina 1000 53
Sumatriptan Oral 100 56 +11 -1 to +23%
Aspirin+metoclopramide Oral 900+10 45
Sumatriptan Oral 100 53 -4 -17 to +8%
L-ASAc+metoclopramide Oral 1620+10 57
Sumatriptan Oral 100 79 +2 -17 to +20%
Tolfenamic acidd Oral 200+200 77
Sumatriptan Oral 100 75 +17 +5 to +28%
Tolfenamic acidd Oral 200+200 58
Placebo 47
Sumatriptan Subc. 6 80 +30 +19 to +41%
Dihydroergota-mine Nasal 1+1 50
Sumatriptan Subc. 6 85 (83%e) +12 +3 to +21%
Dihydroergota-mine Subc. 1+1 73 (86%e) (-3e) (-11 to +5%e)
Sumatriptan Nasal 20 63 +12 +4 to +20%
Dihydroergota-mine 1+1 51
Sumatriptan Subc. 6 91 +17 +8 to +27%
L-ASAc I.v. 1800 74
Sumatriptan Rectal 25 63 -10 -18 to –2%
Ergotamine+caffeine Rectal 2+200 73
Eletriptan 80 68 +35 +26 to +44%
Ergotamine+caffeine 2+200 33
Eletriptan 40 54 +21 +11 to +30%
Ergotamine+caffeine 2+200 33
Rizatriptan 10 76 +29 +19 to 38%
Ergotamine+caffeine 2+200 47
aA decrease from severe or moderate headache to none or mild after 2 h; bCIs; clysine acetylsalicylate; drapid release formulation; eafter 4 h
administration such as the rectal and intranasal route can
be tried. Subcutaneous sumatriptan 6 mg is the most effec-
tive triptan but also the triptan with the most frequent
adverse events [9, 11]. The clinical use of subcutaneous
sumatriptan is hampered by its very high cost of €30 per
injection for 6 mg.
Frequent use of triptans can result in medication-
overuse headache and the limit seems to be a maximum of
9 days per month [5, 22]. It is important to note that pre-
ventive treatment is not effective during medication-
overuse headache.
Ergot alkaloids
Ergotamine [23, 24] is not the drug of first choice for the
treatment of migraine attacks. It has an effect on the 5-
HT1B/1D receptor but also an effect on 5-HT2A (results in
general vasoconstriction) and dopamine D2 receptor (can
result in nausea/vomiting) [25]. It can be used in patients
with infrequent long-standing attacks with multiple
relapses with triptans. In 5 RCTs ergotamine resulted in
less relapses than triptans (Tfelt-Hansen, personal obser-
vation). Oral ergotamine has an extremely low (<1%) and
erratic bioavailability and if ergotamine is used it should
be administered by the rectal route in doses of 1–2 mg
[25]. The most frequent adverse event of ergotamine is
nausea, which often limits its use. Frequent (10 days or
more per month) intake of ergotamine can result in
headache-overuse headache [5] and rarely in overt ergo-
tism, which can be treated with a nitroglycerin infusion
[26].
DHE acts on the same receptors as ergotamine but the
intrinsic activity is apparently less for the 5-HT2A receptor,
resulting in less general vasoconstriction [27–29].
Similarly, DHE is less emetic than ergotamine (dopamine
D2) [23]. DHE can be used parenterally [30] or by the
nasal route [23, 24] in the treatment of migraine attacks.
For adverse potential events of DHE, see ref. [31].
Use of prokinetic drugs and neuroleptics
During migraine attacks the stomach is relatively atonic
and the absorption of orally administered drugs is delayed
[32], but the absorption can be normalised by the proki-
netic and anti-emetic drug metoclopramide [33]. The
combination of lysine acetylsalicylic acid and meto-
clopamide (56%) was as effective as sumatriptan 100 mg
(53% relief) and both were superior to placebo (24%) in
one RCT [34]. Trimebutine is also a prokinetic drug and
in one RCT the combination of trimebutine plus rizatrip-
tan (73% pain-free) was superior to rizatriptan alone (42%
pain-free) [35, 36]. The 42% pain-free is similar to what
was found in a meta-analysis for rizatriptan 10 mg [7, 8]
and the combination with trimebutine thus resulted in a
considerable increase of efficacy. One cannot exclude,
however, that trimebutine per se has an antimigraine
effect and further placebo-controlled studies are needed.
The use of prokinetic medicines can probably increase the
effect of other acute migraine drugs.
Parenteral neuroleptic medicines can be used in the
emergency department. Prochlorperazine given intra-
venously or intramuscularly has been shown to be effec-
tive in several placebo-controlled RCTs [37].
Potential new drugs for acute migraine
The triptans are 5-HT1B/1D receptors and it is important for
future drug development to investigate what sub-type of
the receptor the antimigraine effect depends on. No 5-
HT1B receptor agonist is available but the 5-HT1D receptor
agonist PNU 142633 (29% relief) was similar to placebo
(40% relief) and thus ineffective in the treatment of
migraine [38]. This result shows that the effect on the 5-
HT1B receptor is needed for the antimigraine effect.
The somatostatin receptor agonist octreotide given in a
dose of 100 µg subcutaneously (14% response) was no
more effective than placebo (20% response) in the treat-
ment of migraine attacks [39]; but octreotide (52%) was
effective in cluster headache in a placebo-controlled
(36%) RCT [40].
Calcitonin gene-related peptide (CGRP) was increased
in the jugular vein during migraine attacks in one study
[41] but not in a recent study [42]. A CGRP infusion can
induce migraine attacks [43]. This is the background for
using a CGRP antagonist in the treatment of migraine. The
CGRP receptor antagonist BIBN4096BS (66%) given
intravenously was superior to placebo (27%) in one recent
RCT [44].
Conclusion from a clinician’s point of view
Patients want to be pain-free, without relapses and have
consistency of response [45]. Current drugs such as the
triptans have been a major step forward in migraine treat-
ment. However, the standard triptan sumatriptan 100 mg
results in only 30% of patients being sustained pain-free
(pain-free after 2 h, no relapse within 24 h, and no use of
escape medication) and other triptans like rizatriptan 10
mg and eletriptan 40 mg are only marginally better [7, 8,
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Table 3 Therapeutic use of marketed triptans in currently recommended doses (for details, see [23])
Contraindications to triptans Ischaemic heart disease, variant angina, cerebral and peripheral vascular disease,
and uncontrolled hypertension. Pregnancy. Use of ergot alkaloids within 24 h. 
Current use or use of MAO-inhibitors within the last 2 weeks. 
Hypersensitivity to the triptan. Hemiplegic and basilar migraine.
Cautious use Patients on SSRIs can be treated with triptans but should be warned about 
the symptoms of the serotonin syndrome.
Recommended doses of triptans Dose Maximum daily dosage
6 mg subcutaneous sumatriptan 12
50–100 mg oral sumatriptan 300
50 mg sumatriptan rapidly dissolving tablets 300
(25 mg tablets available in the US)
20 mg intranasal sumatriptan 40
25 mg sumatriptan as suppositories 50
2.5–5 mg oral zolmitriptan 0
2.5 mg orally melting tablets of zolmitriptan 10
2.5 mg oral naratriptan 5
10 mg oral rizatriptana 20
10 mg oral rizatriptan wafera 20
40 mg oral eletriptan 80
12.5 mg oral almotriptan 25
2.5 mg frovatriptan 5?
Clinical efficacy in the treatment of migraine attacks Subcutaneous sumatriptan (6 mg)>eletriptan (40 mg)≥oral sumatriptan 
(50–100 mg)=intranasal sumatriptan (20 mg)=rectal sumatriptan (25 mg)=
oral zolmitriptan (2.5–5 mg)=oral rizatriptan (10 mg)>oral sumatriptan (25 mg),
oral naratriptan (2.5 mg)=oral frovatriptan (2.5 mg).
Speed of onset of effect compared with placebo Subcutaneous sumatriptan (10 min)> intranasal sumatriptan (15 min) > oral 
sumatriptan = oral eletriptan = oral rizatriptan (30 min)> rectal sumatriptan (30–
60 min)> oral zolmitriptan and oral naratriptan (60 min).
It should be noted, however, that these “early responses”, apart from subcuta
neous sumatriptan, are often of relative small magnitude.
Speed of onset of effect compared directly among Oral rizatriptan > oral sumatriptan. Oral rizatriptan = oral zolmitriptan.
two triptans or two administration forms of a triptan Oral rizatriptan > oral naratriptan. Intranasal sumatriptan  > oral sumatriptan.
Adverse events with triptans So-called “triptan” symptoms: tingling, numbness, warm/hot sensation, pressure
or tightness in different part of the body, including chest and neck. 
Rarely regular chest pain. Dizziness and sedation. Naratriptan and almotriptan 
cause no more adverse events than placebo.
Choice of form of administration Tablets generally most convenient.
If severe nausea/vomiting is present the patient could alternatively 
use an injection, nasal spray or a suppository.
Additional dose if the first dose of a triptan is not effective There is no evidence that a second dose of a triptan increases the efficacy. 
Instead patients should if the chosen dose of a triptan is ineffective try 
another dose or different forms of administration or another triptan.
Relapse or secondary treatment failure Most triptans have the same relapse rate of 20-40%.
Naratriptan have in some trials a lower relapse rate than sumatriptan 
and could be tried in relapse-prone patients. 
Cont. next page
13]. The majority of patients are thus not treated optimal-
ly with currently available therapy and there is still ample
room for improvement.
Acute pharmacotherapy of tension-type headache
In RCTs aspirin and paracetamol were superior to place-
bo [46]. The most commonly used dose is 1000 mg for
both drugs. The following NSAIDs were superior to
placebo in the treatment of tension-type headache:
ibuprofen, ketoprofen, naproxen sodium and diclofenac
potassium [46]. The low proportion (17–32%) of patients
becoming pain-free 2 h after dosing underscores the
insufficiency of these drugs [46] and there is therefore
clearly room for better acute therapy of tension-type
headache. Aspirin, paracetamol and NSAIDs should not
be used on a daily basis [5].
The fixed combination of aspirin, paracetamol and caf-
feine was superior to the single substances and the combi-
nation of aspirin and paracetamol in one RCT for time to
50% reduction in pain [47]. One should, however, be care-
ful with frequent use of such a combination because of the
risk of medication-overuse headache.
Acute pharmacotherapy of cluster headache
Oxygen was, in one RCT [48], better than air and is the
first choice in the acute treatment of cluster headache. It
is, however, often impractical to bring a tank around in
case an attack occurs outside home. In clinical practice
not all patients respond to oxygen.
The attacks of cluster headache are short-lived (maxi-
mum 3 h) and non-oral routes of administration of drugs
should be used. Subcutaneous sumatriptan is the most
effective treatment, but very costly, see above. In one
RCT, sumatriptan (74% relief) was superior to placebo
(26% relief) already after 15 min [49]. Intranasal suma-
triptan 20 mg (57% relief) was superior to placebo (26%
relief) after 30 min [50]. In another RTC zolmitriptan 10
mg (62% relief) was superior to placebo (21% relief)
after 30 min [51].
Usually the triptans are limited to 2 doses per day.
Some patients have more cluster headache attacks than
that per day and triptans are not effective in all patients.
Furthermore, some patients cannot afford triptans.
Preventive therapy of cluster headache is therefore still
the first priority.
Table 3 cont.
Use of a second dose for the treatment of a relapse A second dose of a triptan will probably be effective,  
when the first dose of a triptan is primarily effective but with multiple relapses for days alternative drugsb should probably be tried.
Abuse or inappropriate use of triptans Triptans should not be used on a daily basis (except in the treatment 
of chronic cluster headache). Set an upper limit of 9 days per months 
with triptan use. Use triptans with extreme caution in previous drug abusers.
Breast feeding Sumatriptan can be used if milk is expressed and discarded for 8 hours 
after the dose. Not recommended with the other triptans.
Possible drug interactions In patients on propranolol 5 mg rizatriptan should used. Eletriptan should 
not be used in patients on CYP3A4 inhibitors.
a5 mg rizatriptan in patients on propranolol; bthis is one of the few possible indications for rectal ergotaminee
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